Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on June 5, 2025
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
GlobeNewswire
·
June 5, 2025
VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
June 5, 2025
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to purchase up …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 5, 2025
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded …
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 5, 2025
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to …
Hydro One and ACT Foundation celebrate more than 25,000 students trained in lifesaving skills
GlobeNewswire
·
June 5, 2025
LINDSAY, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- Today, the Advanced Coronary Treatment (ACT) Foundation joined Hydro One Inc. (Hydro One) and partners at I.E. Weldon Secondary School in Lindsay to mark the milestone of more than 25,000 Haliburton – …
Hydro One et la Fondation ACT célèbrent la formation de plus de 25 000 élèves aux techniques de secourisme
GlobeNewswire
·
June 5, 2025
LINDSAY, Ontario, 05 juin 2025 (GLOBE NEWSWIRE) -- Aujourd’hui, la Fondation des soins avancés en urgence coronarienne (ACT) s’est jointe à Hydro One Inc. (Hydro One) et à ses partenaires de l’école secondaire I.E. Weldon à Lindsay pour souligner le jalon …
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements
GlobeNewswire
·
June 5, 2025
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on June 4, 2025, it received a written notification from The …
Nanotechnology in Cancer Treatment Market Positioned for Transformational Growth by 2029
GlobeNewswire
·
June 5, 2025
Boston, June 05, 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally, nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale drug delivery systems and precision-targeting techniques, …
FDA Approved Anticancer Peptide Drug Conjugate Market Clinical Trials Insight
GlobeNewswire
·
June 5, 2025
Delhi, June 05, 2025 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market, Drug Sales, Price, Dosage and Clinical Trials Insight 2030 Report Highlights: Global Peptide Drug Conjugate Market Opportunity: > USD 1400 Million Global Peptide Drug Conjugate …
Roquette Appoints Thierry Fournier as Chief Executive Officer
GlobeNewswire
·
June 5, 2025
Roquette Appoints Thierry Fournier as Chief Executive Officer Lille, France, June 5, 2025 - Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, announces the appointment of …
Roquette nomme Thierry Fournier au poste de Directeur Général
GlobeNewswire
·
June 5, 2025
Roquette nomme Thierry Fournier au poste de Directeur Général Lille, France, 5 juin 2025 - Roquette, un leader mondial des ingrédients d’origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé, de la nutrition et de la bio- …
The Foundation for Sarcoidosis Research and American Thoracic Society Announce Dr. Mark Mallozzi as the New FSR/ATS Partner Grant Awardee
GlobeNewswire
·
June 5, 2025
CHICAGO, June 05, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) are pleased to announce that Mark Mallozzi, MD, MPH has been selected to receive the 2025 ATS/FSR Partner Grant, awarded to …
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight
GlobeNewswire
·
June 5, 2025
New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight The dilated cardiomyopathy market is experiencing …
Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight
GlobeNewswire
·
June 5, 2025
New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, …
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
GlobeNewswire
·
June 5, 2025
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
GlobeNewswire
·
June 5, 2025
PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the …
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
GlobeNewswire
·
June 5, 2025
IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after six months in both dose groups, although more robust with the full dose Six-month data …
Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance des anticorps et l’innocuité de son vaccin à dose unique contre le chikungunya IXCHIQ® chez les enfants
GlobeNewswire
·
June 5, 2025
IXCHIQ® a été bien toléré par les enfants âgés d’un à onze ans indépendamment de la dose de vaccin reçue (dose complète ou demi-dose) ou d’une précédente infection au virus du chikungunya Les niveaux d’anticorps demeurent élevés après six mois dans les …
Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt
GlobeNewswire
·
June 5, 2025
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge und …
Merus N.V. annonce la fixation du prix de l’offre publique d’actions ordinaires
GlobeNewswire
·
June 5, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus », la « Société », « nous » ou « notre/nos », une société spécialisée dans l’oncologie développant des anticorps …